Bringing hope through science
Presentation of the Year-end Report 2022
Oncopeptides published its report for the fourth quarter and the 2022 year-end report on February 16, and hosted a webcast on the same day. The event was hosted by CEO Monica Shaw, together with CFO Holger Lembrér and CSO Jakob Lindberg. The presentations was held in English.
Released
Year-end report 2022
"Pepaxti represents true innovation and an improved clinical experience that benefit patients"
CEO Monica Shaw
See the Webcast
For further information, please contact:
Rolf Gulliksen
Global Head of Corporate Communications
Q1 report May 4, 2023
rolf.gulliksen@oncopeptides.com
+46 70 262 96 28
Press release -
Oncopeptides receives a research grant from Sweden´s Innovation Agency to explore the PDC platform in solid tumors
Read press release
Upcoming events
Monica Shaw appointed CEO
On January 4, 2023, Oncopeptides announced that the Board of Directors has appointed Dr Monica Shaw as Chief Executive Officer, CEO, of Oncopeptides. She replaces Jakob Lindberg, who has been the CEO since November 15, 2021. Lindberg assumes his previous position as Chief Scientific Officer. These changes are effective immediately.
Jakob Lindberg interviewed by Di.TV regarding the leadership change
On Wednesday January 4, Jakob Lindberg was interviewed by by the Swedish economy TV channel Di.TV regarding the announced leadership change in Oncopeptides. Jakob Lindberg comments on his resignation as CEO of Oncopeptides and the appointment as Chief Scientific Officer.
CEO Jakob Lindberg interviewed by Di.TV regarding the Q3 report and the EU and US market
On November 9, 2022, CEO Jakob Lindberg was interviewed by Börsmorgon in the Swedish Dagens Industri Di.TV regarding the Q3 report and the EU and US market. See the interview by clicking the link below. The interview is in Swedish.
Tyska lanseringen av Pepaxti - presentation
Fredagen den 21 oktober kl.14.00, 2022, håller Oncopeptides en presskonferens för att prata om den tyska lanseringen av Pepaxti®.
Webcast - CHMP issues a positive opinion recommending full approval of Oncopeptides Pepaxti in EU
June 23, 2022, the European Medicines Agency´s (EMA) Committee for Medicinal Products for Human Use (CHMP), has unanimously adopted a positive opinion recommending a full marketing authorization approval (MAA) of Pepaxti® (melphalan flufenamide, also called melflufen) in EU.
Investors, financial analysts, and media were invited to participate in a webcast with a Q&A session on June 27, 2022, at 11:00 (CET). The event was hosted by CEO Jakob Lindberg, CMO Klaas Bakker and CFO Annika Muskantor.
Vision of Oncopeptides
“Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”
Cultures & Values
We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.
Released
Annual Report 2021
Rolf Gulliksen
Global Head of Corporate Communications
rolf.gulliksen@oncopeptides.com
+46 70 262 96 28
Journey of innovation
Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden's leading cancer researchers and cancer research institutions.
Read more